PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

PharmaEngine, Inc.

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

智擎生技製藥股份有限公司 is involved in the pharmaceutical industry, focusing on the development of anticancer drugs utilizing nanotechnology and checkpoint kinase inhibitors, self-described as a virtual pharmaceutical company.

Metric
Company Name	PharmaEngine, Inc.	Sierra Oncology
Symbol	4.16K
MSH ID	COM:PHARMAENGINE	COM:SIERRAONCOLOGY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	TW	GB
Stage
Employee Count	17
Website	pharmaengine.com	sierraoncology.com
LinkedIn
Founders

Metric
Market Cap	421.83M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	23.68M
Revenue (LTM)
Revenue (NTM)
Gross Profit	22.18M
EBITDA	8.83M
Operating Income	8.55M
Net Income	8.47M
EPS	0.06
Diluted EPS	0.06
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.95
Operating Profit Margin	0.48
EBITDA Margin	0.37
Net Profit Margin	0.42
Return on Equity	0.09
Return on Assets	0.09
Return on Capital Employed	0.11

COM:PHARMAENGINE

智擎生技製藥股份有限公司

Last Close

111.50

14/02 05:30

Market Cap

13.67B

Beta: -

Volume Today

2.05M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	52.81
P/B Ratio	4.02
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	18.90
EV Multiple	43.58

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	268.03
Operating Cycle	402.71
Cash Conversion Cycle	297.78
Asset Turnover	0.20

Metric
Operating Cash Flow	7.93M
Free Cash Flow	7.90M
Cash Flow to Debt	42.40
Operating Cash Flow/Sales	0.38
Free Cash Flow Yield	0.01

Metric
Cash & Equivalents	27.01M
Accounts Receivable	-425.91K
Inventory	490.54K
Goodwill
Debt to Capitalization	0.00
Debt to Assets	0.00
Current Ratio	61.92
Quick Ratio	46.50

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.39
SG&A to Revenue	0.12